Company intelligence / Profile preview
Curileum Discovery
Harrow, England, United Kingdomventureradar.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
Developing ULI-015, a small molecule that reduces polyp formation and progression to colorectal cancer by up to 10-fold in preclinical models. Also developing CSR-1 drug target to address chronic inflammation in IBD and bowel cancer, and ATZ stem cell therapy for Crohn's fistulising disease.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small moleculesstem cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seeking licensing partnerships with pharmaceutical and biotechnology companies
Beyond the preview
Go deeper on Curileum Discovery.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curileum Discovery.